Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults

This phase 3 trial evaluated a bivalent RSV prefusion F protein-based vaccine (RSVpreF) in adults aged 60 and older. Involving over 34,000 participants, the vaccine showed 66.7% efficacy against RSV-associated lower respiratory tract illness with ≥2 symptoms, 85.7% efficacy with ≥3 symptoms, and 62.1% efficacy against RSV-associated acute respiratory illness. Safety data showed higher local reactions with the vaccine than placebo (12% vs. 7%), but systemic events were comparable (27% vs. 26%). Serious adverse events were rare and similar between groups. The results support RSVpreF as a promising intervention for protecting older adults from RSV disease.

This phase 3 trial evaluated a bivalent RSV prefusion F protein-based vaccine (RSVpreF) in adults aged 60 and older. Involving over 34,000 participants, the vaccine showed 66.7% efficacy against RSV-associated lower respiratory tract illness with ≥2 symptoms, 85.7% efficacy with ≥3 symptoms, and 62.1% efficacy against RSV-associated acute respiratory illness. Safety data showed higher local reactions with the vaccine than placebo (12% vs. 7%), but systemic events were comparable (27% vs. 26%). Serious adverse events were rare and similar between groups. The results support RSVpreF as a promising intervention for protecting older adults from RSV disease.